This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform And A Rapidly Ageing Population Provide Strong Stimulus For Growth

NEW YORK, March 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth http://www.reportlinker.com/p01154051/China-Pharmaceutical-Market-Outlook---Government-Incentives-Healthcare-Reform-and-a-Rapidly-Ageing-Population-Provide-Strong-Stimulus-for-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth

Summary

GBI Research's new report: "China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth" provides in-depth analysis of the trends, issues and challenges facing the Chinese pharmaceutical market. It details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie. It includes information on the regulatory guidelines for the manufacture, development and distribution of pharmaceuticals. The report also covers information on the competitive landscape in the Chinese pharmaceutical market, identifying market leaders and key trends in investment. It also includes the key drivers and barriers of the pharmaceutical market in more detail. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

China is currently one of the most important markets in the pharmaceutical industry. It is the most populous country in the world, with a recorded population of over 1.34 billion as of 2011. The country has the second-largest economy after the US with a GDP of $7.3 trillion as of 2011, and its economy is one of the fastest growing in the world, with average growth of 10.6% over the last decade (World Bank, 2012). China is the world's largest exporter and second-largest importer of goods.

In 2011, China overtook Germany to become the third largest pharmaceutical market in the world, and is predicted to overtake Japan by 2015 to become the second largest. In 2011, its estimated value was approximately $64 billion. The size of China's pharmaceutical market is primarily a result of its large population rather than its maturity, as it is still an emerging market. The Chinese pharmaceutical market has the world's largest manufacturing capabilities, producing more than 4,500 drugs and exporting various pharmaceutical products such as acetylsalicylic acid and metamizole to the global market. Recent healthcare reforms have been driving the pharmaceutical market by increasing public access to drugs. In addition, recent population changes such as a majority move from rural to urban China, a rapidly aging community and an increasing overweight population are driving the value of the Chinese pharmaceutical market.

Scope

The report analyzes the Chinese pharmaceutical market, looking at - - Macroeconomic analysis of China covering economic, demographic and market-specific indicators- Market analysis of segments such as branded and generic drugs, prescribed and OTC drugs, and biopharmaceuticals- Industry landscape, looking at pharmaceutical pricing policies, supply chain, drug regulations and healthcare reforms- Competitive profiling of major domestic and international companies operating in the Chinese pharmaceutical market in addition to the important M&A deals in recent years- Drivers and barriers of the Chinese pharmaceutical market

Reasons to buy

The report will enhance your decision-making capability by allowing you to - - Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong growth- Devise a more tailored country strategy through understanding key drivers of and barriers to the pharmaceutical market- Develop key strategic initiatives by understanding leading companies' key focus areas- Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs